StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.28−0.04 (-13.08%)

Close on Nov 20, 2026Market cap $1.43MP/E –Yield –

RedHill Biopharma gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2024 it was $4.85M, up 58.0% from the year before. The highest annual figure on record is $36.35M in fiscal 2021.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$4.85M+58.0%
FY2023Dec 31, 2023$3.07M-89.2%
FY2022Dec 31, 2022$28.46M-21.7%
FY2021Dec 31, 2021$36.35M+32.3%
FY2020Dec 31, 2020$27.47M+581.2%
FY2019Dec 31, 2019$4.03M-27.0%
FY2018Dec 31, 2018$5.52M+193.6%
FY2017Dec 31, 2017$1.88M+1762.4%
FY2016Dec 31, 2016$101.00K+3266.7%
FY2015Dec 31, 2015$3.00K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2022Jun 30, 2022$9.35M+475.4%
Q2 FY2021Jun 30, 2021$10.91M+5071.6%
Q2 FY2020Jun 30, 2020$6.71M–
Q2 FY2019Jun 30, 2019$1.14M–
Q2 FY2018Jun 30, 2018$1.63M–
Q2 FY2017Jun 30, 2017$211.00K–

More RedHill Biopharma figures

See a number that looks wrong?